Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab and Fluzoparib in Relapsed Ovarian Cancer
NCT06446206Phase 2Not yet recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of adebrelimab, fluzoparib in ovarian cancer, sponsored by The First Hospital of Jilin University. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
adebrelimabfluzoparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06446206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06446206.